Virtu Financial LLC Purchases New Stake in LAVA Therapeutics (NASDAQ:LVTX)

Virtu Financial LLC acquired a new position in LAVA Therapeutics (NASDAQ:LVTX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,103 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.08% of LAVA Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Pathway Financial Advisors LLC grew its stake in shares of LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after purchasing an additional 42,500 shares during the period.

LAVA Therapeutics Stock Up 4.2 %

Shares of LVTX stock opened at $1.03 on Friday. LAVA Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $6.47. The firm’s 50 day moving average price is $1.62 and its two-hundred day moving average price is $1.78. The stock has a market cap of $26.11 million, a price-to-earnings ratio of -1.00 and a beta of 0.43.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LVTX. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. HC Wainwright lowered their price objective on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday. Finally, Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, LAVA Therapeutics has a consensus rating of “Hold” and a consensus price target of $3.33.

LAVA Therapeutics Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.